Drug Information

Drug General Information
Drug ID
D0JT5I
Former ID
DIB018024
Drug Name
PF-04457845
Drug Type
Small molecular drug
Indication Liver disease [ICD9: 570-574; ICD10:K70-K77] Phase 2 [541799]
Formula
C23H20F3N5O2
InChI
InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)
InChIKey
BATCTBJIJJEPHM-UHFFFAOYSA-N
PubChem Compound ID
24771824
PubChem Substance ID
49693786, 57449440, 124963756, 125085479, 137190699, 152258570, 160647405, 162223203, 163643070, 178103305, 186007063, 198971245, 224214109, 227264026, 243340664, 251963201, 252442681, 252480464
Target and Pathway
Target(s) Fatty-acid amide hydrolase Target Info Inhibitor [531512]
BioCyc Pathway Anandamide degradation
KEGG Pathway Retrograde endocannabinoid signaling
PANTHER Pathway Anandamide degradation
References
Ref 541799(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6694).
Ref 531512Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.